Pharmafile Logo

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, “Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.” Dive into key findings on HCPs’ preferences for virtual and hybrid meetings, revealing their desire for frequent interactions and the impactful use of their insights. Discover why virtual options are favored for their convenience, inclusivity, and lower environmental impact.

Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in remote or underserved communities is common.

These days, pharmaceutical companies have a choice between hosting meetings in person, virtually, or using a hybrid approach. In making this choice, the cost and organizer’s preference are usually key considerations, but very few people ask the participants what they prefer.

To help answer this question and elucidate the preferred meeting format, frequency, and follow-up approach, we conducted a short feedback survey among HCPs participating in virtual advisory boards in 2022 and 2023. The results were recently published in Pharmaceutical Medicine.

Key findings included that:

  • The majority of health care providers prefer virtual or hybrid pharmaceutical meetings/advisory boards over in-person-only meetings.
  • Health care providers prefer to meet at least 2–4 times per year and want to receive continuous updates on how the pharmaceutical company is using their insights.
  • Key benefits of virtual versus in-person meetings include their superior convenience and flexibility, low environmental impact, and the ability to hear from more diverse participants.

Access the full article here, titled Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Leveraging Real-Time Health Data for Proactive, Predictive Care

Alex Gilbert, Head of Digital Medicines Development & Life Sciences Partnerships at Huma, explores virtual & decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking...

Top 10 Tips for “Virtualizing” In-person Meetings

While Pharma was already slowly pivoting towards virtual events as a substitute for, or supplement to, in-person meetings, COVID-19 quickly changed virtual events from a nice-to-have to a must. With...

Virtualizing Healthcare with Human-Centric Technology

Dr. Patrick Carroll, Chief Medical Officer at Vida Health, discusses the importance of using a “whole health” approach to chronic disease management, how and why the human connection with a...

Importance of Diversity in Pharma and Clinical Trials

No matter which sector you work in, diversity and inclusion are must-haves!

Case Study: Reducing Travel-Related Emissions and Costs Through Virtual Events

In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees....

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating...

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Online Advisory Boards: Top 10 Frequently Asked Questions

It’s hard to imagine a time when some people in the life science industry had never attended a web meeting. Yet, that’s the reality we were living in just two...

Top 10 Tips for Creating Company Culture in a Virtual World

For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn...

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...